The Effect of Darapladib on Plasma Lipoprotein-Associated Phospholipase A2 Activity and Cardiovascular Biomarkers in Patients With Stable Coronary Heart Disease or Coronary Heart Disease Risk Equivalent: The Results of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Study
J Am Coll Cardiol Mohler et al.
51: 1632
Online Appendix
Online Appendix
Files in this Data Supplement:
|